Discrete PEG Constructs Monodisperse Biodistribution Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional polymeric PEGylation technologies face challenges with biocompatibility issues, such as immunogenicity, hydrophobicity, aggregation, and limited design options, leading to characterization and reproducibility problems, and are unable to achieve precise control over biodistribution and pharmacokinetics of therapeutic and diagnostic agents.
Innovation Solution
The development of substantially pure linear multifunctional discrete polyethylene glycol (dPEG) constructs that can be attached to biologically active groups, allowing for precise control of biodistribution and pharmacokinetics by modulating the chemical connections and attachment cores, enabling the creation of stable and targeted diagnostic and therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymeric PEGylation technology is used, then PEGylation can be achieved, but biocompatibility issues arise including immunogenicity, hydrophobicity, aggregation, and limited design options
Solution Approach 1:
The patent segments the polymeric PEG structure into discrete, monodisperse PEG units with defined molecular weights (e.g., dPEG2, dPEG4, dPEG6). This segmentation eliminates the polydispersity and heterogeneity of conventional polymeric PEGs, resulting in constructs with uniform size and composition that reduce immunogenicity and aggregation while maintaining biocompatibility.
Solution Approach 2:
The patent changes the critical parameter of molecular weight distribution from polydisperse to monodisperse. By using discrete PEG units with precise molecular weights (e.g., 2 kDa, 4 kDa, 6 kDa) rather than a distribution of sizes, the invention achieves improved biocompatibility, reduced immunogenicity, and enhanced reproducibility while maintaining the desired PEGylation function.
2Manufacturing precision
If conventional polymeric PEGylation is used, then PEGylation can be achieved, but characterization and reproducibility problems occur
Solution Approach 1:
The patent segments the polymeric PEG into discrete, monodisperse units with defined molecular weights. This segmentation enables precise characterization using standard analytical techniques (mass spectrometry, HPLC, NMR) and ensures reproducible manufacturing by eliminating the size distribution variability inherent in polymeric PEGs.
Solution Approach 2:
The patent replaces the complex,难以characterized polymeric structure with simpler, discrete molecular constructs that can be precisely measured and characterized using conventional analytical methods, thereby improving both characterization ease and manufacturing reproducibility.
3Manufacturing precision
If conventional polymeric PEGylation is used, then PEGylation can be achieved, but precise control over biodistribution and pharmacokinetics cannot be achieved
Solution Approach 1:
The patent segments PEG into discrete units (dPEG2, dPEG4, dPEG6) that can be precisely controlled in number and arrangement. This enables fine-tuned control over the pharmacokinetic properties of conjugated molecules by adjusting the number and position of discrete PEG units, while maintaining versatility through different attachment patterns and molecular weights.
Solution Approach 2:
The patent changes the molecular weight parameter from a continuous distribution (polymeric) to discrete, defined values (monodisperse). This parameter change enables precise control over biodistribution and pharmacokinetics by selecting specific discrete PEG unit sizes and numbers, while maintaining design flexibility through various attachment configurations.
Data Source
AI summary
Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEGx can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and “hidden”; (c or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.